Diabetic Nephropathy: Pathophysiology, Stages, Diagnosis & Management

Diabetic Nephropathy (DN) — formerly "DM Nephrology" — is the leading cause of end-stage kidney disease (ESKD) globally. It affects ~30–40% of diabetics.

Pathophysiology

  • Chronic hyperglycemia → advanced glycation end-products (AGEs), PKC activation, oxidative stress
  • Hemodynamic: Afferent/efferent arteriolar dysregulation → glomerular hypertension, hyperfiltration → sclerosis
  • Inflammatory: TGF-β, VEGF, MCP-1 → fibrosis, angiogenesis
  • Podocyte injury → albuminuria → tubulointerstitial inflammation

Stages (KDIGO / ADA)

StageGFR (mL/min/1.73m²)Albuminuria (ACR mg/g)Clinical
1: Hyperfiltration>90<30 (A1)Renal enlargement, ↑ GFR
2: Normoalbuminuric DKD60–89<30 (A1)Early structural change, no albuminuria
3: Microalbuminuria60–8930–299 (A2)Incipient nephropathy
4: Macroalbuminuria30–59≥300 (A3)Overt nephropathy; ↑ CVD risk
5: ESKD<15VariableRenal replacement therapy needed

Diagnosis & Monitoring

  • Annual Screening: UACR (spot urine) + eGFR (CKD-EPI)
  • Confirm: 2 of 3 abnormal UACR in 3–6 months
  • Exclude Non-Diabetic Kidney Disease: Hematuria, active sediment, rapid decline, no retinopathy → consider biopsy

Multifactorial Management (ABCDE)

TargetGoalAgents
A: A1c<7% (individualized)SGLT2i, GLP-1 RA, insulin
B: Blood Pressure<130/80ACEi/ARB (max tolerated), +CCB/thiazide
C: CholesterolStatin ± ezetimibeHigh-intensity statin if ASCVD/10-yr risk ≥20%
D: Diet / LifestyleLow Na (<2g), plant-dominant, exercise, smoking cessationRenal dietitian referral
E: ESKD Prep / SGLT2iSGLT2i if eGFR ≥20 (↓ ESKD 30–40%)Dapagliflozin, empagliflozin, canagliflozin

Key Advances

  • SGLT2 Inhibitors: Cardio-renal protection independent of glucose
  • Finerenone (non-steroidal MRA): ↓ CKD progression in T2D + albuminuria
  • GLP-1 RAs: Weight, glucose, albuminuria reduction

Early detection + RAAS blockade + SGLT2i = paradigm shift from "inevitable decline" to "modifiable trajectory."

Kidney Disease - Related Articles